# Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia

> **NCT05943314** · NA · WITHDRAWN · sponsor: **Guangzhou Bio-gene Technology Co., Ltd**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CLL1/+CD33 CAR-T

## Key facts

- **NCT ID:** NCT05943314
- **Lead sponsor:** Guangzhou Bio-gene Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-07-12
- **Primary completion:** 2023-08-28
- **Final completion:** 2023-08-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The clinical trial was terminated due to a change in sponsor strategy.
- **Last updated:** 2023-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05943314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05943314, "Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05943314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*